Investigational Approaches to Antiretroviral Therapy
|
|
- Gwendolyn Terry
- 6 years ago
- Views:
Transcription
1 Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners will be able to: Discuss the appropriate use of novel antiretroviral agents Identify new approaches for treating people with HIV infection Slide 3 of 4 Investigational Approaches to Antiretroviral Therapy Are there any new options for initial treatment of HIV? Are two antiretrovirals as good as (or better than) three? Updates on 2- drug therapy What are the options in someone who has difficulty taking daily drugs? Long-acting agents in development What are new medicines for treating someone with multi-drug resistant HIV? What s on the horizon? Slide 4 of 4
2 Slide 7 of 4 New Antiretroviral Drugs New medications in current classes Bictegravir (INSTI) (approved Feb 218) Doravirine (NNRTI) Bictegravir (BIC) Unboosted integrase inhibitor; high in vitro genetic barrier to resistance, low potential for drug interactions Phase 3 trials in treatment naïve people: BIC/FTC/TAF vs DTG/ABC/3TC; BIC/FTC/TAF vs. DTG + FTC/TAF BIC non inferior to DTG in terms of virologic suppression; no resistance 1,2 As compared to DTG/ABC/3TC, similar changes in estimated GFR, tubular proteinuria, bone mineral density and lipids Randomized switch studies in virologically suppressed persons: Switching to BIC/FTC/TAF non-inferior to continuing boosted PI 3 or a DTG, ABC, 3TC-containing regimen 4 Slide 8 of 4 1 Gallant J et al, Lancet 217; 2 Sax P et al Lancet 217; 3 Daar E et al IDWeek Molina J-M et al, CROI 218 abstract 22 Bictegravir/FTC/TAF: Treatment Naïve Trials Study ,2 Study 149 3,4* -.6% -3.5% (-4.8 to 3.6%) (-7.9 to 1.%) Proportion of Participants, % HIV-1 RNA < 5 c/ml 1 B/F/TAF (n=314) ABC/3TC/DTG (n=315) HIV-1 RNA No HIV-1 RNA 5 c/ml Data HIV-1 RNA < 5 c/ml B/F/TAF (n=32) DTG + FTC/TAF (n=315) HIV-1 RNA No HIV-1 RNA 5 c/ml Data Slide 9 of 4 Bictegravir/FTC/TAF has non-inferior efficacy vs DTG-containing regimens in treatment-naïve populations at Week 48 Gallant J et al, Lancet 217; Sax P et al Lancet 217
3 Slide 1 of 4 Bictegravir/FTC/TAF Indications: Initial treatment of adults with HIV Replacement for regimen in persons who are virologically suppressed and have no history of treatment failure or known resistance to its components Pharmacology and dosing: One-pill, once a day, with or without food. Not recommended if estimated CrCL <3 ml/minute Drug resistance: Active in vitro against HIV isolates that carry some integrase resistance mutations Efficacy in people with prior INSTI failure or resistance is unknown Bictegravir/FTC/TAF Drug interactions: Rifampin contraindicated; other rifamycins not recommended. Metformin AUC increased 39%; no effect on glucose 1 ; assess benefit/risk BIC chelated by polyvalent cations; time doses according to label Pregnancy: Not recommended -- insufficient safety data Side effects: Diarrhea, nausea and headache Increase in serum creatinine (median.1 mg/dl) because of inhibition of tubular secretion Slide 11 of 4 1 Custodio J et al ID Week 217, 1386 Doravirine (DOR): Investigational NNRTI Active in vitro against HIV that is resistant to first-generation NNRTI (isolates with K13N, Y181C, G19A, E11K, E138K, K13N/Y181C) 1 Once daily without regard to food Low potential for drug interactions In phase 3 clinical trial (DRIVE- FORWARD) 2, DOR non-inferior to darunavir/r in terms of virologic suppression with superior lipid profile 1 Lai AAC 214;58: Molina JM, et al, CROI 217, Abstract 45LB Slide 12 of 4
4 Slide 13 of 4 DRIVE-AHEAD: Doravirine/3TC/TDF in Treatment-Naïve Persons With HIV Infection Phase 3 Double-blind Treatment-naïve HIV RNA 1 copies/ml Stratified by HIV RNA HCV or HBV allowed Doravirine/3TC/Tenofovir DF (n=364) Efavirenz/FTC/Tenofovir DF (n=364) Week Primary outcome: HIV RNA <5 copies/ml (FDA snapshot algorithm). Primary Endpoint Non-inferiority: -1%. HIV RNA <5 copies/ml Baseline demographics: Male: 85%. Age: 3-32 years. White: 48%. History of AIDS: 14%. HIV RNA: log 1 copies/ml. CD4: cells/mm 3. Squires KE, et al. J Int AIDS Soc. 217;2(suppl 4): Abstract TUAB14LB DRIVE-AHEAD: Doravirine/3TC/TDF in Treatment-Naïve Persons With HIV Infection DOR/3TC/TDF non-inferior to EFV/FTC/TDF at Wk 48 in terms of virologic suppression HIV RNA >5: ~1% in each arm Virologic failures in DOR arm (6%) Primary NNRTI resistance: 1.6% Primary NRTI resistance: 1.4% DOR superior to EFV in terms of lower incidence of neuropsychiatric adverse events; more favorable changes in lipids New drug applications for DOR/TDF/3TC and for DOR alone submitted to FDA in Jan 218; PDUFA date: Oct 218 Patients (%) HIV RNA <5 Copies/mL Doravirine/3TC/TDF Difference (%): 3.5 (-2., 9.) 1 91% 91% 84% 81% Overall ITT (n=364/364) 1K (n=277/258) Efavirenz/FTC/TDF 81% 81% >1K (n=69/73) HIV RNA (copies/ml) (Observed Failure Approach) Slide 14 of 4 Squires KE, et al. J Int AIDS Soc. 217;2(suppl 4): Abstract TUAB14LB; Orkin C et al, CROI 218, abstract 491 OR FEW Slide 16 of 4
5 Slide 17 of 4 Current NRTI-limiting Regimens for Initial Therapy LPV/r + 3TC (GARDEL) 1 Non-inferior to LPV/r + 2 NRTI Disadvantages: high pill burden, toxicities DRV/r + RAL (NEAT1) 2,3 Non-inferior to DRV/r + TDF/FTC CD4 <2: DRV/r + RAL inferior to DRV/r + 2 NRTI VL >1 K: more failures with DRV/r + RAL 1 Cahn P et al, Lancet ID 214; 2 Raffi F et al, Lancet, 214; 3 Lambert-Niclot S et al, J Antimicrob Chemother, 216; 4 Figueroa MI et al, 15 th EACS, 215 Dolutegravir + 3TC for Initial Therapy PADDLE: single arm study 2 pts with VL <1K: HIV RNA <5 in 9% at wk 48 ACTG A5353: Phase 2 single-arm study HIV RNA 1 to <5, 12 participants enrolled Week 24, HIV RNA <5 in 9% Virologic failure (n=3); suboptimal adherence 1 person: R263RK and M184V ACTG A5353 Wk 24 Virologic Outcomes Baseline HIV RNA GEMINI-1 and -2: ongoing phase 3 trials; results anticipated this year Figueroa MI et al, 15 th EACS, 215. Taiwo BO et al, Clin Infect Dis, 217. >1K (n=37) 1K (n=83) VL <5 (%) 89 9 Virologic non-success (%) HIV RNA >5 copies/ml Other reasons 8 2 Slide 18 of 4 DRV/r + 3TC for Initial Therapy Randomized trial (ANDES) DRV/r + 3TC (n=75) DRV/r + 3TC/TDF (n=7) VL <5 at wk 48: 93 94% Baseline VL >1K: high response rate Dual therapy non-inferior to triple therapy at wk48 Promising results; larger trial ongoing Patients (%) HIV RNA <5 (ITT) Darunavir/r +: 3TC 3TC + tenofovir DF Difference (%): -1.% (-7.5 ; 5.6%) 93% 94% 1 91% 92% Overall (n=7/66) Baseline HIV RNA >1K Copies/mL (n=2/12) Slide 19 of 4 Figueroa et al, CROI 218, Abstract 489
6 Slide 2 of 4 Switching to NRTI-limiting regimens after virologic suppression (maintenance) LPV/r + 3TC/FTC (OLE) 1 ATV/r + 3TC (SALT, ATLAS-M) 2-3 DRV/r + 3TC (DUAL) 4 DRV/r + RPV (small trial, n=6) 5 DRV/r + DTG (DUALIS) being studied DTG + 3TC (LAMIDOL, ASPIRE favorable results 6,7 ; TANGO large RCT just launched 8 ) 1 Arribas JR et al, Lancet ID, 215; 2 Perez-Molina JA et al, Lancet ID, 215; 3 Di Giambenedetto S et al, J Antimicrob Chemother 217; 4 Pulido T HIV Drug Therapy 216 Glasgow, O331; 5 Maggiolo F, JAIDS, 216; 6 Joly V et al CROI 217, abstract 458; 7 Taiwo B et al CID, 217 ; 8 Switching to DTG + RPV in Virologically Suppressed Patients: SWORD-1 and -2 Pts on stable 1 st or 2 nd ART (no change due to VF) and VL <5 for >12 mo. Randomized 1:1 to continue antiretroviral regimen (CAR) or switch to DTG + RPV DTG + RPV non-inferior to CAR DTG/RPV single pill regimen available Food, acid lowering therapy, cation considerations Slide 21 of 4 HIV RNA <5, % Virologic outcomes at wk DTG + RPV (n=513) CAR (n=511) 5 4 <1 1 <1 1 Virologic Virologic No virologic success non-response data Llibre JM et al. CROI 217; Abstract 44LB.; Llibre JM et al, Lance 218 LATTE-2: Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy Cabotegravir (integrase inhibitor) and rilpivirine (NNRTI): long-acting formulations 1,2 LATTE-2: Phase 2a 3 Open-label 18 years of age ART-naïve CD4 2 Creatinine clearance 5 No HBV or ALT 5x ULN Slide 23 of 4 *In virologically suppressed patients, oral RPV added during last 4 weeks of induction phase. Qualification for maintenance phase: HIV RNA <5 between wk -4 and day 1. Baseline characteristics: Median age: 35 years. Male: 92%. Median HIV RNA: 4.4 log 1 copies/ml. HIV RNA >1K copies/ml: 18%. Median CD4: 489 cells/mm Spreen HIV Clin Trials 213;14: Spreen JAIDS 214;67: Margolis DA, et al. Lancet. 217Jul 21. [Epub ahead of print].
7 LATTE-2: Virologic Outcomes With LA Cabotegravir + Rilpivirine as Maintenance Therapy HIV RNA <5 Copies/mL (%) % 87% 94% Week 96 Results Oral cabotegravir + 3TC/ABC daily (n=56) IM cabotegravir + IM rilpivirine Every 4 weeks (n=115) Every 8 weeks (n=115) 4% 2% % 2% Success Failure No Virologic virologic failure: q8 week 8 [no resistance]) [INI + NRTI Data Protocol-defined weeks (n=2 at weeks 4 and 48 resistance]) and oral cabotegravir (n=1 at 14% Injection site reactions: mild/moderate; transient High participant satisfaction Ongoing phase 3 trials (FLAIR, ATLAS): every 4-wk dosing; results in 218 ATLAS-2M: every 8-wk dosing; results in % Slide 24 of 4 Eron J, et al. J Int AIDS Soc. 217;2(suppl 4): Abstract MOAX25LB. Margolis DA, et al. Lancet. 217Jul 21. [Epub ahead of print]. Long-acting NRTI: MK-8591 (EFdA) Slide 25 of 4 Nucleoside RT translocation inhibitor (NRTTI) Half life of active anabolite: 8-13 hr Humans: single oral dose as low as.5 mg suppressed HIV RNA for >7 day Study in healthy volunteers: multiple daily doses as low as.25 mg expected to lead to HIV suppression Phase 2b trial in people with HIV, in combination with DOR and 3TC, has started (DRIVE2Simplify) Daily dosing Phase 1b, single-dose, monotherapy study Study population: ART naïve (N=3) Grobler CROI 217 #435 Matthews IAS 217 #TUPDB22LB Matthews RP CROI 218 #26 Long-acting NRTI: MK-8591 (EFdA) Animals: drug accumulates in lymph nodes, vagina, rectum Oral MK-8591, even at low doses, protects monkeys from rectal SHIV challenge Parenteral dosing: 6-12 months Supports possible role in PrEP Grobler CROI 216 #98 Friedman CROI 216 #437LB Grobler CROI 217 #435 Markowitz IAS 217 #MOAX23LB Markowitz CROI 218, #89LB Adapted from slide by Trip Gulick, MD Slide 26 of 4
8 Slide 27 of 4 6 yo F diagnosed with HIV in 199. Multiple previous regimens HIV RNA 2,; CD4 cell count 15 HIV phenotype: resistance to NRTI, NNRTI, PIs. Sensitive to INSTI Which of the following classes of drugs is in phase 3 clinical trials? 1. Entry/attachment inhibitors 2. Maturation inhibitors 3. Capsid inhibitors 4. Broadly neutralizing antibodies Case Scenario New Medications for Multi-drug Resistant HIV in Phase 3 trials Ibalizumab Fostemsavir Slide 28 of 4 HIV Entry Inhibitors CD4 Binding Coreceptor Binding Virus-Cell Fusion fostemsavir ibalizumab gp41 gp12 V3 loop CCR5 Inhibitors maraviroc* enfuvirtide* CD4 Slide 29 of 4 Cell Membrane * = FDA approved CCR5/CXCR4 (R5/X4) Slide courtesy of Trip Gulick, MD; Adapted from Moore JP, PNAS 23;1:
9 A Approved 3 Slide 3 of 4 Humanized monoclonal Ab: binds CD4 on host cells; blocks HIV entry (post attachment inhibitor) 1 Active against CCR5 and CXCR4 tropic HIV No cross resistance with other ARVs 2 IV infusion: 2, mg loading dose then 8 mg every 2 wks Duration of infusion: 15-3 min Ibalizumab 1 Emu B et al, Abstract 1686, IDWeek 217; 2 Weinheimer S et al, CROI 218 Ibalizumab in Persons with Multi-Drug Resistant HIV Slide 31 of 4 Phase 3 trial: 4 heavily treatment experienced pts with 3-class ARV resistance Primary endpt: VL drop >.5 log 1 c/ml: 3% during control period 83% after loading dose After loading dose, regimen optimized to include 1 active drug Wk 24: VL <2 in 5% Expanded access: viral suppression to wk 48 March 6, 218 Emu B et al, Abstract 1686, IDWeek Fostemsavir (FTR): Oral HIV Attachment Inhibitor Prodrug of temsavir: binds to gp12, inhibits HIV attachment to CD4 Phase 3 trial in heavily treatment experienced patients with virologic failure (BRIGHTE) Kozal M et al, 16th EACS, 217 Slide 32 of 4
10 Slide 33 of 4 Fostemsavir (FTR): Phase 3 Trial (BRIGHTE) Adjusted Mean (95% CI) Mean VL Change at day 8 N=69 N=21 Placebo FTR 6mg BID Difference (95% CI) = (-.81, -.441) P<.1 Virologicresponse through wk 24 (observed analysis) Kozal M et al, 16th EACS, 217 Regulatory submissions are currently anticipated to take place in the 219/22 timeframe At wk 24, 54% of randomized and 36% of non-randomized ppts who received FTR + OBR achieved VL <4 Monoclonal Antibody against CCR5: PRO 14 Weekly subcutaneous injection Single drug maintenance of suppression study 1 : 1 pts had virologic suppression for 2 yr (out of 31 who entered) One week randomized placebo controlled phase 2b/3 trial in combination with existing ART in people failing current ART 2 N=52; CCR5 tropic HIV Resistance to 3 ARV classes or 2 or more classes with limited treatment options At 1 week, statistically significant reduction in HIV RNA of >.5 log 1 c/ml with PR 14 vs placebo Participants continuing for additional 24 weeks with weekly PRO 14/optimized ART Slide 34 of 4 1 Lalezari J et al, CROI 217, abstract 437; 2 HIV Maturation Inhibitors (MI) Slide courtesy of Trip Gulick, MD Treated with maturation inhibitor Immature virus Slide 35 of 4 Morales-Ramirez IAS 217 #MOAB13:BMS /GSK development halted due to GI toxicity
11 36 On the Horizon Broadly neutralizing antibodies Other novel agents Slide 36 of 4 Broadly Neutralizing Antibodies against HIV Slide 37 of 4 Slide courtesy of Pablo Tebas, MD Scheid J et al, Nature, 216 Slide 38 of 4 Similar results with VRC1. Bar K et al, NEJM 216 Combination bnab, long-acting bnab being studied for treatment, prevention
12 Slide 39 of 4 Other investigational drugs in the pipeline: Investigational Approaches to Antiretroviral Therapy Slide 4 of 4 New options for initial treatment: Bictegravir/FTC/TAF approved; Doravirine (NNRTI) under FDA review Two-drug therapy advancing: DTG + 3TC and DRV/r + 3TC being studied for initial therapy; DTG/RPV approved for maintenance What are the options in someone who has difficulty taking daily drugs? Long-acting agents in development: LA-CAB/LA-RPV in phase 3 trials; MK-8591 (EFdA); others What do you give to someone with highly drug resistant HIV? Ibalizumab approved; fostemsavir completed phase 3; PRO 14, other agents being developed What s on the horizon? broadly neutralizing antibodies, and many others!!
Investigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationInvestigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents
Investigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents Joseph J. Eron MD Professor of Medicine University of North Carolina Chapel Hill, North Carolina Learning Objectives
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationLong-Acting Antiretrovirals for HIV
Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City Disclosures None Single Tablet
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationRoy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York
Antiretroviral Therapy: Investigational New Drugs and New Strategies Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York FORMATTED: MM/DD/YY Antiretroviral
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationNew options for new and old patients. Antonella Castagna
New options for new and old patients Antonella Castagna Disclosures I have received funding for Advisory Boards, Speaker Panels and for preparation of educational materials from the following: Gilead Sciences
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationUpdate From the 2018 Conference on Retroviruses and Opportunistic Infections
Slide 1 of 51 Update From the 2018 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Emory University Atlanta, Georgia Learning Objectives After attending
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationSimplified regimens: Pros and Cons
Rio de Janeiro, 2018 Simplified regimens: Pros and Cons Pedro Cahn Treatment Strategies: A long way Monotherapy Dual therapy STIs Triple therapy Non daily regimens Simplification Mega HAART Long Acting/Extended
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationAntiretroviral Treatment: What's in the Pipeline
Antiretroviral Treatment: What's in the Pipeline Joseph P. McGowan, MD, FACP, FIDSA Professor of Medicine Hofstra North Shore-LIJ School of Medicine October 14, 2015 Which describes best how HIV Maturation
More informationLong Acting ART for Treatment and PrEP
Long Acting ART for Treatment and PrEP Anton Pozniak MD FRCP Consultant Physician Disclosures I have received honoraria, travel sponsorship and research grants from: Gilead Sciences Janssen MSD ViiV Healthcare
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationState of the art of ART
No disclosures State of the art of ART Medical Management of AIDS December 7, 2017 Monica Gandhi MD, MPH Professor of Medicine, Division of HIV, Infectious Diseases and Global Medicine, UCSF Medical Director,
More informationNew Drugs in Development Are We Ready for Long-Acting ART?
New Drugs in Development Are We Ready for Long-Acting ART? Melanie A. Thompson, MD Principal Investigator AIDS Research Consortium of Atlanta Atlanta, Georgia Learning Objectives After attending this presentation,
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationReduced drug regimens. Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona
Reduced drug regimens Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona jmllibre@flsida.org 9th IAS Conference on HIV Science (IAS 2017) 23 26 July
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationHIV IS NOT OVER. Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Learning Objectives
Update From the Conference on Retroviruses and Opportunistic Infections (CROI) Davey M. Smith, MD, MAS Professor of Medicine University of California San Diego San Diego, California Learning Objectives
More informationFuture Perspectives for Delivery of Antiretroviral Drugs
Future Perspectives for Delivery of Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie,
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationViiV Healthcare Investor and Analyst Update 24 July 2018
ViiV Healthcare Investor and Analyst Update 24 July 2018 Cautionary statement regarding forward looking statements This presentation may contain forward-looking statements. Forward-looking statements give
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationTerapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R
Terapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Gilead Board Member/Advisory Panel: MSD, Gilead, Janssen,
More informationWhat is the virological support for reduced drug regimens?
What is the virological support for reduced drug regimens? Pr Anne-Genevieve Marcelin Pitié-Salpêtrière Hospital UMR 1136 University Pierre et Marie Curie Paris, France Disclosure of Personal and Commercial
More information4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections
Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationAcquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Acquired INSTI Resistance Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting honoraria, speaker
More information2-Drug regimens in HIV Anton Pozniak MD FRCP
2-Drug regimens in HIV Anton Pozniak MD FRCP Advantages Cost Dual Therapy Toxicities of Nukes CV risk, bone, renal disease Smaller STRs Keep drugs for later etc. Dual Therapy-Talking Points - What are
More informationX Congreso Nacional de GESIDA Sesión Plenaria GESIDA Nuevas Modalidades de Tratamiento Antirretroviral
X Congreso Nacional de GESIDA Sesión Plenaria Nuevas Modalidades de Tratamiento Antirretroviral Dr. José M. Miró Servicio de Enfermedades Infecciosas Hospital Clínic - IDIBAPS Universidad de Barcelona
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationReport Back: HIV Treatment Updates
Report Back: HIV Treatment Updates Catherine Koss, MD Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine Zuckerberg San Francisco General Hospital University of California, San
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationThe injectables: a new silver bullet?
The injectables: a new silver bullet? Geneva October 6 Francois Venter Wits Reproductive Health and HIV Institute Thanks Clinical Care Options, Helen Rees, Joe Eron, Wits RHI sex worker team Disclosures
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationWhat is the magic number? Clinical perspective
What is the magic number? Clinical perspective Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena UOC Malattie Infettive AOU Senese Outline Regimens with reduced number of drugs Use
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More information23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationAntiretroviral Therapy: Case-Based Panel Discussion
Antiretroviral Therapy: Case-Based Panel Discussion Rajesh T. Gandhi, MD Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More informationHIV Treatment Update
HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures Consulting, Advisory Boards,
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationHIV Update Four Corners Conference Linda Gorgos, MD, MSc, FIDSA Southwest Care Center Santa Fe, NM
HIV Update Four Corners Conference 2018 Linda Gorgos, MD, MSc, FIDSA Southwest Care Center Santa Fe, NM Disclosures Our clinic receives funding for clinical trials from Gilead, Abbvie, Janssen, Merck,
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationPretreatment drug resistance and new treatment paradigms in firstline
Michelle Moorhouse October 2018 27 th International Workshop on HIV Drug Resistance and Treatment Strategies Pretreatment drug resistance and new treatment paradigms in firstline ART Disclosures/disclaimers
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationDebating view on less ART. Strategies under evaluation
Debating view on less ART Strategies under evaluation Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena Department of Infectious Diseases, Siena University Hospital, Italy Conflicts
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationSingle Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era
Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon
More informationhiv treatmen + bulletin (e) july-august 2017 htb(e): volume 18 number 7/8 Published by HIV i-base C O N T E N T S
ISSN 1472-4863 htb(e): volume 18 number 7/8 hiv treatmen + bulletin (e) july-august 2017 C O N T E N T S EDITORIAL 2 SUPPLEMENTS 2 2017 Pipeline Report Fit For Purpose: treatment optimisation i-base FUNDING
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationNew Delivery Systems and Long Acting Antiretroviral Drugs
New Delivery Systems and Long Acting Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Prague October 2018 Disclosures Honoraria received for advisory boards
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More information